Review confirms reduced severity of SARS-CoV-2 Omicron infection

In a recent study posted to the Research Square preprint* server, researchers review existing literature to quantify the transmissibility, immune evasion, reinfection, and severity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

Study: Omicron SARS-CoV-2 Variant of Concern: A Review on its Transmissibility, Immune Evasion, Reinfection, and Severity. Image Credit: M.Aka / Shutterstock.com

Study: Omicron SARS-CoV-2 Variant of Concern: A Review on its Transmissibility, Immune Evasion, Reinfection, and Severity. Image Credit: M.Aka / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

As a result of its high transmissibility, the SARS-CoV-2 Omicron variant is rapidly spreading across the world. In the United States, for example, this strain of SARS-CoV-2 is responsible for 95% of all new coronavirus disease 2019 (COVID-19) cases since January 1, 2022.

Extensive research is needed to understand the extent to which the increased transmissibility and virulence of Omicron threaten public health globally. Furthermore, it is also crucial to determine how the global population should recognize these dynamics, perceive risk, and adhere to public health and social measures amid the emergence of the Omicron variant.

About the study

In the present study, the researchers performed a literature search in PubMed, Web of Science, Scopus, ScienceDirect, Google Scholar, medRxiv, and bioRxiv using keywords such as Omicron, transmissibility, immune evasion, reinfection, and severity to find articles published in 2021 and 2022. Data reviewed in the present study included all the existing articles having at least one of these keywords.

Study findings

In one Norwegian study, among 117 people in a party that was 96% fully vaccinated, 74% got infected with Omicron after coming in contact with one individual from South Africa, from where Omicron was originally detected. Moreover, a study conducted in the United Kingdom found that the Omicron variant had a 10 times greater risk of reinfection than the Delta variant.

In another study conducted in South Africa, substantial population-level evidence was acquired which demonstrated that Omicron, in contrast to the Beta and Delta variants, evades immunity from prior infection. Similarly, in a large-scale study conducted in Denmark, the researchers found that although there was no significant difference in transmissibility for Omicron and Delta among unvaccinated people, the Omicron variant was 2.6-3.7 times more infectious than the Delta variant among vaccinated people.

Among studies discussing the severity of Omicron infections, one study conducted by researchers from the University of Edinburgh in Scotland indicated that when compared to the Delta variant, Omicron resulted in a two-thirds reduction in the probability of COVID-19 hospitalization. Notably, existing literature demonstrated that Omicron infections are much less severe than Delta variant infections.

When assessing the clinical severity of the SARS-CoV-2 Omicron variant using nationwide data, researchers in South Africa found that people with Omicron infection had an 80% lower risk of hospitalization than those without Omicron infection.

In another study, the researchers compared the clinical characteristics of 466 patients infected with Omicron and admitted to a hospital in Tshwane, South Africa to 3,962 hospital admissions from earlier COVID-19 waves. To this end, the length of hospital stay was only 4.0 days for Omicron infection, which was comparable to the average hospital stay of 8.8 days during earlier waves.

Conclusions

Taken together, the current study revealed that Omicron spreads faster than previous SARS-CoV-2 variants. This is likely due to the ability variant of this to evade immune responses induced by vaccination and previous infections.

Omicron also has several times higher odds of infecting vaccinated and previously infected people than Delta and other SARS-CoV-2 variants. However, the risk of infection from Delta and Omicron is almost similar among unvaccinated people.

Almost all the studies reviewed in the current work consistently showed that the severity of infection in Omicron cases is much lower compared to Delta and other previous variants. Subsequently, there is a considerably lower risk of requiring hospital admission, intensive care unit (ICU) admission, and mechanical ventilators in Omicron-infected individuals. Furthermore, Omicron infections were associated with shorter hospital stays and lower mortality rates. Although Omicron has an enhanced ability to escape immunity developed by vaccines, booster doses significantly protect individuals from symptomatic COVID-19 infections.

Therefore, the authors strongly recommend the continuance of usual prevention measures, such as vaccination, masking, and suitable infection mitigation strategies for decreasing Omicron transmission, reducing morbidity and death to ultimately reduce the workload of healthcare systems globally.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 12). Review confirms reduced severity of SARS-CoV-2 Omicron infection. News-Medical. Retrieved on November 18, 2024 from https://www.news-medical.net/news/20220203/Review-confirms-reduced-severity-of-SARS-CoV-2-Omicron-infection.aspx.

  • MLA

    Mathur, Neha. "Review confirms reduced severity of SARS-CoV-2 Omicron infection". News-Medical. 18 November 2024. <https://www.news-medical.net/news/20220203/Review-confirms-reduced-severity-of-SARS-CoV-2-Omicron-infection.aspx>.

  • Chicago

    Mathur, Neha. "Review confirms reduced severity of SARS-CoV-2 Omicron infection". News-Medical. https://www.news-medical.net/news/20220203/Review-confirms-reduced-severity-of-SARS-CoV-2-Omicron-infection.aspx. (accessed November 18, 2024).

  • Harvard

    Mathur, Neha. 2023. Review confirms reduced severity of SARS-CoV-2 Omicron infection. News-Medical, viewed 18 November 2024, https://www.news-medical.net/news/20220203/Review-confirms-reduced-severity-of-SARS-CoV-2-Omicron-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Early RSV vaccination in pregnancy provides best protection for newborns